1. A compound, including enantiomers, stereoisomers, and tautomers of said compound and pharmaceutically acceptable salts solvates or derivatives thereof, with said compound having the general structure shown in formula (I):
wherein
R is hydrogen, hydroxy, C1-4alkoxy or amino;
R1 is naphthyl, substituted phenyl, C6-12arylC1-4alkyl, C6-12arylsulfonyl or heteroaryl, and wherein said naphthyl, aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-6alkyl, C1-6alkenyl, fluoroalkyl or fluoroalkoxy of the formula CnHxFy or OCnHxFy wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is 2n+1, C1-4alkoxy, C1-4thioalkyl, hydroxy, hydroxyC1-4alkyl, C1-4acyloxy, nitro, amino, C1-4alkylamino, C1-4dialkylamino, aminoC1-4alkyl, C1-4alkylaminoC1-4 alkyl, C1-4dialkylaminoC1-4alkyl, \u2014CN, \u2014CO2H, \u2014CO2C1-4alkyl, \u2014NHCOC1-4alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted pyrrolyl and substituted or unsubstituted pyridyl;
R2 and R3 are the same or different and are each independently selected from: hydrogen, C1-4alkyl, C1-4dialkylaminoC1-4alkyl, pyrrolidinylC1-4alkyl, imidazolyl or heterocycle selected from morpholinyl, thiomorpholinyl, aziridinyl, pyrrolidinyl, piperidinyl, azepanyl, piperazinyl, diazepanyl, diazabicyclo2.2.1hept-2-yl and triazocanyl; and wherein said heterocycle is optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, oxo, \u2014CHO and \u2014CO2C1-4alkyl; or
R2 and R3 taken together with the nitrogen atom to which they are attached form an imidazolyl or a heterocycle selected from morpholinyl, thiomorpholinyl, aziridinyl, pyrrolidinyl, piperidinyl, azepanyl, piperazinyl, diazepanyl, diazabicyclo2.2.1hept-2-yl and triazocanyl; and wherein said heterocycle is optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, oxo, \u2014CHO, \u2014CO2C1-4alkyl, hydroxyC1-4alkyl, oxiranylC1-4alkyl, dihydroxyC1-4alkyl, \u2014(CH2)aN\u2014CO2C1-4alkyl, hydroxyl, and \u2014(CH2)aOPO(OC1-4alkyl)2, wherein a is an integer from 1 to 4;
R4 is C1-4alkyl, fluoroalkyl or fluoroalkoxy of the formula CnHxFy or OCnHxFy wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is 2n+1, C1-4alkoxy or C1-4thioalkyl; and
X and Y are CH.
2. The compound as set forth in claim 1, which is selected from the group consisting of:
2-(piperazin-1-yl)-1-(3-nitrophenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-methoxyphenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-tert-butylphenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-bromophenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-chlorophenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(3-chloro-4-fluorophenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(3-methoxyphenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-thiomethylphenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(3-fluorophenyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(3-methylphenyl)-1H-indole-3-carboxaldehyde,
1-(4-tert-butylphenyl)-2-piperazin-1-yl-1H-indole-3-carboxaldehyde,
1-(4-tert-butylphenyl)-2-piperidin-1-yl-1H-indole-3-carboxaldehyde,
1-(3-formylphenyl)-2-(piperazin-2-yl)-1H-indole-3-carboxaldehyde,
1-(biphenyl-4-yl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde hydrochloride,
1-(4-ethylphenyl)-2-(piperazin-1-y)-1H-indole-3-carboxaldehyde hydrochloride,
1-(3-bromophenyl)-2-piperazin-1-yl-1H-indole-3-carboxaldehyde,
1-(4-methyl-3-nitrophenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde,
1-(4-dimethylaminophenyl)-2-piperazin-1-yl-1H-indole-3-carboxaldehyde,
1-(4-phenoxyphenyl)-2-piperazin-1-yl-1H-indole-3-carboxaldehyde,
1-(4-methylphenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde,
1-(4-fluorophenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde hydrochloride,
1-(3-chlorophenyl-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(4-vinylphenyl)-1H-indole-3-carboxaldehyde,
1-(3-hydroxymethylphenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde,
1-(3-ethoxyphenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde,
1-(4-butylphenyl)-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde hydrochloride,
N-{3-3-formyl-2-(piperazin-1-yl)-indol-1-ylphenyl}-acetamide hydrochloride,
4-3-formyl-2-(piperazin-1-yl)-indol-1-yl-benzonitrile, and
2-piperazin-1-yl-1-(4-pyridin-4-yl)phenyl-1H-indole-3-carboxaldehyde.
3. The compound as set forth in claim 1, which is selected from the group consisting of:
1-(4-tert-butylphenyl)-2-4-(2-hydroxyethyl)piperazin-1-yl-1H-indole-3-carboxaldehyde,
phosphoric acid 2-{4-1-(4-tert-butylphenyl)-3-formyl-1H-indol-2-yl-piperazin-1-yl}-ethyl ester diethyl ester hydrochloride,
1-(4-tert-butylphenyl)-2-(4-methyl-piperazin-1-yl)-1H-indole-3-carboxaldehyde,
4-1-(4-tert-butylphenyl)-3-formyl-1H-indol-2-ylpiperazine-1-carboxylic acid tert-butyl ester,
5-1-(4-tert-butylphenyl)-3-formyl-1H-indol-2-yl-2,5-diazabicyclo2.2.1heptane-2-carboxylic acid tert-butyl ester,
1-(4-tert-butyl-phenyl)-2-(2-methyl-aziridin-1-yl)-1H-indole-3-carboxaldehyde,
4-3-formyl-1-(4-iodophenyl)-1H-indol-2-yl-piperazine-1-carboxylic acid tert-butyl ester,
4-1-(4\u2032-cyanobiphenyl-4-yl)-3-formyl-1H-indol-2-yl-piperazine-1-carboxylic acid tert-butyl ester, and
4-{1-4-(tert-butoxylcarbonyl-1H-pyrrol-2-yl)-phenyl-3-formyl-1H-indol-2-yl}-piperazine-1-carboxylic acid tert-butyl ester.
4. The compound as set forth in claim 1, wherein R2 and R3 taken together with the nitrogen atom to which they are attached form imidazolyl.
5. The compound as set forth in claim 4, wherein said compound is 2-imidazol-1-yl-1-phenyl 1H-indole-3-carboxaldehyde.
6. The compound as set forth in claim 1, wherein R2 is hydrogen or methyl, and R3 is dimethylaminoethyl, pyrrolidinylethylamino, and piperidinyl.
7. The compound as set forth in claim 6, wherein said compound is selected from the group consisting of:
2-(2-dimethylaminoethylamino)-1-phenyl-1H-indole-3-carboxaldehyde,
2-(methylpiperidin-4-yl)amino-1-phenyl-1H-indole-3-carboxaldehyde,
1-(4-tert-butylphenyl)-2-(2-dimethylaminoethyl)-methylamino-1H-indole-3-carboxaldehyde,
1-(4-tert-butylphenyl)-2-(2-dimethylaminoethylamino)-1H-indole-3-carboxaldehyde, and
1-(4-tert-butylphenyl)-2-(2-pyrrolidin-1-yl-ethylamino)-1H-indole-3-carboxaldehyde hydrochloride.
8. The compound as set forth in claim 1, wherein R1 is benzyl, naphthyl, thienyl, pyridinyl, and benzenesulfonyl.
9. The compound as set forth in claim 8, which is selected from the group consisting of:
2-(piperazin-1-yl)-1-benzyl-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(1-naphthyl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(thien-3-yl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(pyridin-2-yl)-1H-indole-3-carboxaldehyde,
2-(piperazin-1-yl)-1-(pyridin-3-yl)-1H-indole-3-carboxaldehyde and
1-benzenesulfonyl-2-(piperazin-1-yl)-1H-indole-3-carboxaldehyde.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for selecting the medium access method in a communications network, using
information exchanged between at least two transmission devices, possibly via a plurality of further transmission devices, on the basis of a further plurality of medium access methods (FDMA, TDMA, CDMA), with each medium access method taking up characteristic resources in each of the transmission devices,
characterized
in that, on the basis of ascertainment of all the available resources in a transmission device, the medium access method which takes up the currently least used resource of this transmission device is set selectively.
2. The method as claimed in claim 1,
characterized
in that a medium access method is set section by section between two respective transmission devices.
3. The method as claimed in claim 1 or 2,
characterized
in that the transmission devices are in the form of subscriber terminals (TLN1, TLNi) or router devices arranged between said subscriber terminals.
4. The method as claimed in claim 1 to 3,
characterized
in that the communications network is of packet-oriented design.
5. The method as claimed in one of the preceding claims,
characterized
in that the information is exchanged on the basis of an Internet protocol (TCPIP) or a protocol (UMTS) used for mobile radio.
6. The method as claimed in one of claims 1 to 5,
characterized
in that the information is exchanged on the basis of an asynchronous transfer mode (ATM).
7. The method as claimed in one of the preceding claims,
characterized
in that the medium access methods is in the form of an FDMA medium access method (FDMA), a TDMA medium access method (TDMA), or a CDMA medium access method (CDMA).